Carcinogenesis, Teratogenesis & Mutagenesis ›› 2023, Vol. 35 ›› Issue (3): 219-223.doi: 10.3969/j.issn.1004-616x.2023.03.011

Previous Articles    

Evaluation of genotoxicity of fungal fibrinolytic compound 1

SHI Wenjing1, TIAN Yijun1, DONG Yachun1, WU Wenhui2, ZHANG Tian2, ZHANG Huishu2, ZHU Yuping3   

  1. 1. Department of Hygeine and Toxicology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433;
    2. Centre for Marine Medicine and Health Food Research, School of Food Science and Technology, Shanghai Ocean University, Shanghai 201306;
    3. Experimental Teaching Center of Basic Medical College, Naval Medical University, Shanghai 200433, China
  • Received:2022-11-23 Revised:2023-03-14 Published:2023-06-03

Abstract: OBJECTIVE:To perform a systematic genotoxicity assessment of fungal fibrinolytic compound 1 (FGFC1) in an established GLP laboratory platform. METHODS:A combination of classical genotoxicity assays (Ames,in vitro culture CHO cell chromosome aberration and mouse bone marrow micronucleus assays) was used to detect genotoxicity of FGFC1. RESULTS:Results from the Ames assay indicate that FGFC1 was not mutagenic to Salmonella typhimurium at five doses of 0.5,5,50,500 and 1 000 g per dish,with and without the addition of the S9 metabolic activation system. FGFC1 did not induce chromosomal aberrations in the presence of S9 after 24 h and 48 h of treatments. The rates of micronucleus induction in bone marrow cells at 3 doses of 62.5,125.0 and 250.0 mg/kg was not significantly different from that in the solvent control group (P>0.05). CONCLUSION:The above results indicate that FGFC1 was not genotoxic and not potentially carcinogenic under the test conditions.

Key words: fungal fibrinolytic compound, Ames test, chromosomal aberration test, micronucleus assay, genetic toxicity

CLC Number: